6 completed, 2 unknown, 1 active not recruiting, 1 not yet recruiting. 10 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 10 | Completed 6, Unknown 2, Active not recruiting 1, Not yet recruiting 1 |
| Phase 2 | 1 | Completed 1 |
Follow Typhoid Fever: new trials by email Literature Review of Typhoid Fever trials Research Report on Typhoid Fever
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ZyVac-TCV Bangladesh Study Purified Vi capsular polysaccharide of Salmonella typhi conjugated to tetanus toxoid as carrier protein (Typhoid Vi Conjugate Vaccine I.P.). Trade name: ZyVac® TCV - Typhoid Vaccination, Typhoid | Phase 3 | Not yet recruiting | International Centre for Diarrhoeal Disease Research, Bangladesh | 4000 | 2025-04-01 | 2025-02-07 |
| Co-administration Study of OCV, TCV and MR Oral Cholera Vaccine (OCV), Typhoid Conjugate Vaccine (TCV), Measles and Rubella (MR) - Typhoid, Cholera | Phase 3 | Unknown | International Centre for Diarrhoeal Disease Research, Bangladesh | 2117 | 2023-10-14 | 2023-10-13 |
| Non-inferiority and Safety Study of EuTCV Compared to Typbar-TCV in Healthy 6 Months-45 Years Aged Participants EuTCV (Vi-CRM Typhoid conjugate vaccine), Typbar-TCV - Typhoid Fever | Phase 2 / Phase 3 | Completed | EuBiologics Co.,Ltd | 444 | 2020-09-07 | 2021-10-07 |
| Immune Equivalence Between Multi-dose and Single Dose Formulation of Vi-DT and Their Overall Safety (Phase III) Vi-DT (Multi-dose formulation), Vi-DT (Single dose formulation), Control Vaccine - Typhoid | Phase 3 | Completed | International Vaccine Institute | 1800 | 2020-02-04 | 2021-08-27 |
| Immune Non-inferiority and Safety of a Vi-DT Typhoid Conjugate Vaccine Test Vaccine Vi-DT Typhoid conjugate, Control Vaccine Typbar TCV® - Typhoid | Phase 3 | Unknown | International Vaccine Institute | 1800 | 2019-11-15 | 2020-04-22 |
| Clinical Efficacy of Typhoid Conjugate Vaccine (Vi-TCV) Among Children Age 9 Months Through 12 Years in Blantyre, Malawi Vi-Typhoid Conjugate Vaccine (Vi-TCV), Meningococcal A Conjugate Vaccine (MCV-A) - Typhoid | Phase 3 | Active not recruiting | University of Maryland, Baltimore | 30000 | 2018-02-21 | 2026-09-17 |
| Nepal Undifferentiated Febrile Illness Trial Azithromycin, Co-trimoxazole - Undifferentiated Febrile Illness | Phase 3 | Completed | Oxford University Clinical Research Unit, Vietnam | 330 | 2016-05-23 | 2023-12-06 |
| Study of a Single Dose of SP093 Typhoid Vi Polysaccharide Vaccine in Japanese Subjects Typhoid Vi polysaccharide - Salmonella Infections, Typhoid Fever | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 200 | 2012-05-01 | 2014-05-12 |
| A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults Typhoid Vi Polysaccharide Vaccine, Yellow Fever Vaccine, Japanese Encephalitis Vaccine - Meningococcal Disease, Meningococcal Meningitis | Phase 3 | Completed | Novartis | 552 | 2011-11-01 | 2014-03-11 |
| Comparative Study in Healthy Adults Aged 18-50 Yrs Administered With Hepatyrix or Havrix+Typherix or Tiphim Vi, to Compare Reactogenicity & Immunogenicity Combined Vi polysaccharide typhoid vaccine and hepatitis A vaccine- Hepatyrix - Hepatitis A | Phase 3 | Completed | GlaxoSmithKline | 1034 | 2002-05-01 | 2016-09-09 |
Bacterial Infections (1) · Cholera (1) · Encephalitis, Japanese (1) · Hepatitis A (1) · Measles (1) · Meningitis, Meningococcal (1) · Meningococcal Infections (1) · Rabies (1) · Rubella (1) · Salmonella Infections (1) · Yellow Fever (1)
Bacterial Infections and Mycoses (10) · Enterobacteriaceae Infections (10) · Gram-Negative Bacterial Infections (10) · Infections (10) · Bacterial Infections (9) · Salmonella Infections (9) · RNA Virus Infections (3) · Virus Diseases (3) · Mononegavirales Infections (2) · Arbovirus Infections (1) · Brain Diseases (1) · Central Nervous System Bacterial Infections (1) · Central Nervous System Diseases (1) · Central Nervous System Infections (1) · Central Nervous System Viral Diseases (1)
Vi polysaccharide vaccine, typhoid (2) · Azithromycin (1) · Carrier Proteins (1) · Cholera Vaccines (1) · Diphtheria Toxoid (1) · Dosage Forms (1) · Japanese Encephalitis Vaccines (1) · MenACWY-CRM vaccine (1) · Rabies Vaccines (1) · Trimethoprim, Sulfamethoxazole Drug Combination (1) · Yellow Fever Vaccine (1)
International Centre for Diarrhoeal Disease Research, Bangladesh (2) · International Vaccine Institute (2) · EuBiologics Co.,Ltd (1) · GlaxoSmithKline (1) · Novartis (1) · Oxford University Clinical Research Unit, Vietnam (1) · Sanofi Pasteur, a Sanofi Company (1) · University of Maryland, Baltimore (1)
Nepal (2) · Philippines (2) · Bangladesh (1) · Czechia (1) · Germany (1) · Japan (1) · Malawi (1)
Buddha Basnyat, MBBS,MSc,MD (1) · Ganesh Kumar Rai, MD (1) · Josefina C Carlos, MD (1) · Matthew Laurens, MD (1) · Md Taufiqul Islam, MBBS, MPH (1)
PMID 24873986, PMID 25308927, PMID 28969659, PMID 30845320, PMID 32991678, PMID 34525285, PMID 34942090, PMID 35664443, PMID 35961356, PMID 36774331, PMID 38281499